• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Celecoxib in arthritis: relative risk management profile and implications for patients.塞来昔布治疗关节炎：相对风险的管理概况及其对患者的影响。
Ther Clin Risk Manag. 2009;5:889-96. doi: 10.2147/tcrm.s3131. Epub 2009 Nov 18.
2
Celecoxib: a review of its use in the management of arthritis and acute pain.塞来昔布：用于关节炎和急性疼痛管理的综述
Drugs. 2007;67(16):2433-72. doi: 10.2165/00003495-200767160-00008.
3
Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.塞来昔布：对其在骨关节炎、类风湿关节炎及急性疼痛治疗中应用的综述。
Drugs. 2000 Apr;59(4):957-80. doi: 10.2165/00003495-200059040-00017.
4
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.环氧化酶-2选择性非甾体抗炎药（依托度酸、美洛昔康、塞来昔布、罗非昔布、艾瑞昔布、伐地昔布和鲁米昔布）用于骨关节炎和类风湿性关节炎：系统评价与经济学评估
Health Technol Assess. 2008 Apr;12(11):1-278, iii. doi: 10.3310/hta12110.
5
Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice.慢性疼痛中的非甾体抗炎药：新数据对临床实践的启示
J Pain Res. 2018 Sep 20;11:1937-1948. doi: 10.2147/JPR.S168188. eCollection 2018.
6
Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?选择性环氧化酶-2抑制剂与心肌梗死：两者联系有多紧密？
Drug Saf. 2002;25(12):829-35. doi: 10.2165/00002018-200225120-00001.
7
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.罗非昔布：其在骨关节炎、急性疼痛及类风湿关节炎治疗中应用的综述
Drugs. 2001;61(6):833-65. doi: 10.2165/00003495-200161060-00019.
8
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.塞来昔布与非甾体抗炎药治疗骨关节炎和类风湿关节炎的胃肠道毒性：CLASS研究：一项随机对照试验。塞来昔布长期关节炎安全性研究。
JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247.
9
Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.联合治疗与单一选择性COX-2药物塞来昔布相比，在关节炎患者中降低胃肠道毒性：患者及成本效益考量
Open Access Rheumatol. 2011 Aug 3;3:53-62. doi: 10.2147/OARRR.S14568. eCollection 2011.
10
Practice Advisory on the Appropriate Use of NSAIDs in Primary Care.基层医疗中合理使用非甾体抗炎药的实践指南
J Pain Res. 2020 Aug 3;13:1925-1939. doi: 10.2147/JPR.S247781. eCollection 2020.

引用本文的文献

1
Dual-Functionalized Mesoporous Silica Nanoparticles for Celecoxib Delivery: Amine Grafting and Imidazolyl PEI Gatekeepers for Enhanced Loading and Controlled Release with Reduced Toxicity.载双功能化介孔硅纳米粒子用于塞来昔布传递：胺接枝和咪唑基聚乙烯亚胺作为门控试剂用于增强载药和控制释放并降低毒性。
Molecules. 2024 Jul 27;29(15):3546. doi: 10.3390/molecules29153546.
2
3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages.3,4-二羟基苯甲异羟肟酸（Didox）抑制TLR4激活的RAW264.7小鼠巨噬细胞中的促炎特征和氧化应激。
Chem Biol Interact. 2015 May 25;233:95-105. doi: 10.1016/j.cbi.2015.03.027. Epub 2015 Apr 2.

本文引用的文献

1
Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.接受双氯芬酸或依托考昔治疗的患者血压变化相关因素：MEDAL研究结果
J Hypertens. 2009 Apr;27(4):886-93. doi: 10.1097/HJH.0b013e328325d831.
2
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.类风湿关节炎患者中风的心血管、风湿和药理学预测因素：一项巢式病例对照研究。
Arthritis Rheum. 2008 Aug 15;59(8):1090-6. doi: 10.1002/art.23935.
3
Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.非甾体抗炎药的环氧化酶选择性与中风风险
Arch Intern Med. 2008 Jun 9;168(11):1219-24. doi: 10.1001/archinte.168.11.1219.
4
The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.选择性和非选择性非甾体抗炎药使用者中严重心血管事件和胃肠道事件之间的平衡。
Ann Rheum Dis. 2009 May;68(5):668-73. doi: 10.1136/ard.2007.087254. Epub 2008 May 21.
5
Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke.非阿司匹林类非甾体抗炎药、环氧化酶-2抑制剂与中风风险
Stroke. 2008 Jul;39(7):2037-45. doi: 10.1161/STROKEAHA.107.508549. Epub 2008 Apr 24.
6
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.环氧化酶-2选择性非甾体抗炎药（依托度酸、美洛昔康、塞来昔布、罗非昔布、艾瑞昔布、伐地昔布和鲁米昔布）用于骨关节炎和类风湿性关节炎：系统评价与经济学评估
Health Technol Assess. 2008 Apr;12(11):1-278, iii. doi: 10.3310/hta12110.
7
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.选择性环氧化酶-2抑制剂、非甾体抗炎药与充血性心力衰竭：新发病例与复发病例的差异
Br J Clin Pharmacol. 2008 Jun;65(6):927-34. doi: 10.1111/j.1365-2125.2008.03121.x. Epub 2008 Apr 1.
8
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.6项随机安慰剂对照试验中塞来昔布的心血管风险：跨试验安全性分析
Circulation. 2008 Apr 22;117(16):2104-13. doi: 10.1161/CIRCULATIONAHA.108.764530. Epub 2008 Mar 31.
9
Late-onset celecoxib-induced combined hepato-nephrotoxicity.迟发性塞来昔布诱导的肝-肾联合毒性。
Br J Clin Pharmacol. 2008 Jul;66(1):150-1. doi: 10.1111/j.1365-2125.2008.03157.x. Epub 2008 Mar 5.
10
The problem with NSAIDs: what data to believe?
Curr Pain Headache Rep. 2007 Dec;11(6):423-7. doi: 10.1007/s11916-007-0228-y.

塞来昔布治疗关节炎：相对风险的管理概况及其对患者的影响。

Celecoxib in arthritis: relative risk management profile and implications for patients.

机构信息

Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK;

出版信息

Ther Clin Risk Manag. 2009;5:889-96. doi: 10.2147/tcrm.s3131. Epub 2009 Nov 18.

DOI:10.2147/tcrm.s3131
PMID:19956553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2781063/
Abstract

Celecoxib is a selective cyclo-oxygenase 2 inhibitor licensed for use in musculoskeletal symptoms as well as in primary dysmenorrhea and acute pain. One advantage celecoxib has over traditional nonsteroidal anti-inflammatory drugs is that of significantly fewer gastrointestinal side-effects associated with its use. Much has been published on the potential cardiovascular and cerebrovascular complications of its administration. This review details the available evidence to allow prescribers to make informed decisions in the light of potentially conflicting evidence. The overall cardiovascular risk is increased with higher doses of celecoxib but is comparable with nonselective nonsteroidal anti-inflammatory use. As with all of these drugs, the potential cardiovascular and gastrointestinal risks of prescription need to be weighed up against possible benefits for each individual patient and discussed with the patients themselves.

摘要

塞来昔布是一种选择性环氧化酶 2 抑制剂，已获准用于治疗肌肉骨骼症状、原发性痛经和急性疼痛。与传统的非甾体抗炎药相比，塞来昔布的一个优势是其使用相关的胃肠道副作用明显较少。关于其使用的潜在心血管和脑血管并发症已经发表了很多文章。本综述详细介绍了现有证据，以便在潜在的相互矛盾的证据下，让处方医生做出明智的决策。较高剂量的塞来昔布会增加心血管风险，但与非选择性非甾体抗炎药的使用相当。与所有这些药物一样，需要权衡每个患者的潜在心血管和胃肠道风险与可能的益处，并与患者本人进行讨论。